The effects of population-based mammography screening starting between age 40 and 50 in the presence of adjuvant systemic therapy

International Journal of Cancer

Volumn 137, Issue 1, 2015, Pages 165-172

  De Gelder, Rianne ^a   Heijnsdijk, Eveline A M ^a   Fracheboud, Jacques ^a   Draisma, Gerrit ^a   De Koning, Harry J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

breast cancer therapy; mammography; mortality; screening

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CONTROLLED STUDY; FEMALE; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; POPULATION RESEARCH; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIMULATION; SURVIVAL RATE; VERY ELDERLY; ADJUVANT CHEMOTHERAPY; BIOLOGICAL MODEL; BREAST NEOPLASMS; EARLY DIAGNOSIS; MORTALITY; NETHERLANDS; PROCEDURES;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; MODELS, BIOLOGICAL; NETHERLANDS; SURVIVAL RATE;

EID: 84930416258     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29364     Document Type: Article

References (37)

1. International Agency for Research on Cancer. Volume 7: Breast Cancer Screening. In:, Vainio H, Bianchini F, eds. IARC Handbooks of Cancer Preventioned. Lyon: IARC Press, 2002. p 1-236.
2. de Koning HJ, Boer R, Warmerdam PG, et al. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. J Natl Cancer Inst 1995; 87: 1217-23.
3. Gotzsche PC, Nielsen M,. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2009: CD001877.
4. Marmot MG, Altman DG, Cameron DA, et al. The benefits and harms of breast cancer screening: an independent review. Br J Cancer 2013; 108: 2205-40.
5. Kalager M, Zelen M, Langmark F, et al. Effect of screening mammography on breast-cancer mortality in Norway. New Engl J Med 2010; 363: 1203-10.
6. Paci E, Group EW,. Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. J Med Screening 2012; 19 (Suppl 1): 5-13.
7. van de Velde CJ, Verma S, van Nes JG, et al. Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer. Cancer Treat Rev 2010; 36: 54-62.
8. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. New Engl J Med 2005; 353: 1784-92.
9. Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L,. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet 2006; 368: 2053-60.
10. Nelson HD, Tyne K, Naik A, et al. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151: 727-37, W237-W242.
11. Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 2009; 151: 738-47.
12. Habbema JD, van Oortmarssen GJ, Lubbe JT, et al. The MISCAN simulation program for the evaluation of screening for disease. Comput Methods programs Biomed 1985; 20: 79-93.
13. van Oortmarssen GJ, Habbema JD, van der Maas PJ, et al. A model for breast cancer screening. Cancer 1990; 66: 1601-12.
14. National Evaluation Team for Breast cancer screening (NETB). National evaluation of breast cancer screening in the Netherlands 1990-2007. Twelfth evaluation report. Rotterdam: Erasmus MC, University Medical Center Rotterdam, Radboud University Nijmegen Medical Centre, 2009.
15. IKCnet. Cijfersoverkanker.nl/. (Last accessed December, 2014).
16. Sukel MP, van de Poll-Franse LV, Nieuwenhuijzen GA, et al. Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990-2006 in the southeastern Netherlands. Eur J Cancer 2008; 44: 1846-54.
17. Struikmans H, Nortier JW, Rutgers EJ, et al. [Guideline 'Treatment of breast cancer 2008' (revision)]. Nederlands tijdschrift voor geneeskunde 2008; 152: 2507-11.
18. Carter CL, Allen C, Henson DE,. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181-7.
19. Michaelson JS, Silverstein M, Sgroi D, et al. The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer 2003; 98: 2133-43.
20. Michaelson JS, Silverstein M, Wyatt J, et al. Predicting the survival of patients with breast carcinoma using tumor size. Cancer 2002; 95: 713-23.
21. Sant M, Allemani C, Capocaccia R, et al. Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer 2003; 106: 416-22.
22. Tabar L, Vitak B, Chen HH, et al. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin North Am 2000; 38: 625-51.
23. Adami HO, Malker B, Holmberg L, et al. The relation between survival and age at diagnosis in breast cancer. New Engl J Med 1986; 315: 559-63.
24. Nystrom L, Andersson I, Bjurstam N, et al. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002; 359: 909-19.
25. Bjurstam N, Bjorneld L, Warwick J, et al. The Gothenburg Breast Screening Trial. Cancer 2003; 97: 2387-96.
26. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
27. van Herk-Sukel MP, van de Poll-Franse LV, Voogd AC, et al. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat 2010; 122: 843-51.
28. Fracheboud J, De Gelder R, Otto SJ, et al.; National evaluation of breast cancer screening in the Netherlands. 1990-2007 (XII). Twelfth evaluation report. Rotterdam: Department of Public Health, Erasmus MC University Medical Center Rotterdam, Department of Epidemiology, Biostatistics and HTA, Radboud University Nijmegen Medical Centre, 2005.
29. Vervoort MM, Draisma G, Fracheboud J, et al. Trends in the usage of adjuvant systemic therapy for breast cancer in the Netherlands and its effect on mortality. Br J Cancer 2004; 91: 242-7.
30. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 352: 930-42.
31. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 351: 1451-67.
32. Holford TR, Cronin KA, Mariotto AB, et al. Changing patterns in breast cancer incidence trends. J Natl Cancer Inst Monogr 2006; 36: 19-25.
33. Helvie MA, Chang JT, Hendrick RE, et al. Reduction in late-stage breast cancer incidence in the mammography era: implications for overdiagnosis of invasive cancer. Cancer 2014; 120: 2649-56.
34. de Gelder R, Fracheboud J, Heijnsdijk EA, et al. Digital mammography screening: Weighing reduced mortality against increased overdiagnosis. Prev Med 2011; 53: 134-40.
35. Hellquist BN, Duffy SW, Abdsaleh S, et al. Effectiveness of population-based service screening with mammography for women ages 40 to 49 years: evaluation of the Swedish Mammography Screening in Young Women (SCRY) cohort. Cancer 2011; 117: 714-22.
36. de Gelder R, Draisma G, Heijnsdijk EA, et al. Population-based mammography screening below age 50: balancing radiation-induced vs. prevented breast cancer deaths. Br J Cancer 2011; 104: 1214-20.
37. Frisell J, Lidbrink E,. The Stockholm Mammographic Screening Trial: risks and benefits in age group 40-49 years. J Natl Cancer Inst Monogr 1997; 22: 49-51.